+
Indegene Unveils NEXT Tool to Automate Medical Writing with GenAI
ECONOMY & POLICY

Indegene Unveils NEXT Tool to Automate Medical Writing with GenAI

Indegene, a digital-first, life sciences commercialization company, today announced the launch of NEXT Medical Writing Automation, an advanced platform that combines deep medical writing expertise with generative AI (GenAI) to accelerate the creation of high-quality, compliant documents across clinical development, regulatory submissions, and beyond.

Medical writing teams are under constant pressure to deliver precise, regulatory-ready documents within tight timelines, often while navigating fragmented data and evolving compliance needs. NEXT Medical Writing Automation addresses these challenges head-on. It combines Indegene’s decades of domain knowledge with the power of its AI engine, Cortex. As a life sciences-specialist knowledge engineering and multi-agent orchestration platform, Cortex by Indegene enables life sciences leaders to adopt and scale this transformative technology with enterprise-grade governance.

Purpose-built by experienced medical writers, NEXT Medical Writing Automation operates within familiar environments like Microsoft Word, auto-generating compliant drafts that adapt to diverse sponsor formats and workflows. It integrates seamlessly with Regulatory Information Management (RIM) systems, maintaining traceability and consistency across documents.

With automated scheduling, intelligent task assignments, and robust data flow integration, NEXT Medical Writing Automation helps life sciences organizations scale operations efficiently while maintaining a strong compliance backbone. As document requirements grow and scrutiny intensifies, such solutions become essential to sustaining operational excellence. “We see this platform as more than automation—it’s about elevating the entire practice of medical writing,” said Sameer Lal, SVP, Enterprise Medical Solutions, Indegene. “Writers can now focus on strategic tasks and critical thinking, while the platform manages the heavy lift of data and formatting.”

The launch of NEXT Medical Writing Automation reinforces Indegene’s commitment to building AI-driven, domain-first solutions that help life sciences organizations modernize critical processes and meet business objectives with confidence.

Indegene, a digital-first, life sciences commercialization company, today announced the launch of NEXT Medical Writing Automation, an advanced platform that combines deep medical writing expertise with generative AI (GenAI) to accelerate the creation of high-quality, compliant documents across clinical development, regulatory submissions, and beyond.Medical writing teams are under constant pressure to deliver precise, regulatory-ready documents within tight timelines, often while navigating fragmented data and evolving compliance needs. NEXT Medical Writing Automation addresses these challenges head-on. It combines Indegene’s decades of domain knowledge with the power of its AI engine, Cortex. As a life sciences-specialist knowledge engineering and multi-agent orchestration platform, Cortex by Indegene enables life sciences leaders to adopt and scale this transformative technology with enterprise-grade governance.Purpose-built by experienced medical writers, NEXT Medical Writing Automation operates within familiar environments like Microsoft Word, auto-generating compliant drafts that adapt to diverse sponsor formats and workflows. It integrates seamlessly with Regulatory Information Management (RIM) systems, maintaining traceability and consistency across documents.With automated scheduling, intelligent task assignments, and robust data flow integration, NEXT Medical Writing Automation helps life sciences organizations scale operations efficiently while maintaining a strong compliance backbone. As document requirements grow and scrutiny intensifies, such solutions become essential to sustaining operational excellence. “We see this platform as more than automation—it’s about elevating the entire practice of medical writing,” said Sameer Lal, SVP, Enterprise Medical Solutions, Indegene. “Writers can now focus on strategic tasks and critical thinking, while the platform manages the heavy lift of data and formatting.”The launch of NEXT Medical Writing Automation reinforces Indegene’s commitment to building AI-driven, domain-first solutions that help life sciences organizations modernize critical processes and meet business objectives with confidence.

Next Story
Infrastructure Energy

Shree Cement Boosts Green Goals with 6 MW Solar Plant in Roorkee

Shree Cement, one of India’s leading cement producers, has commissioned a 6.0 MWp solar power plant at its Roorkee unit in Uttarakhand. Strategically located next to its existing cement operations, the plant marks a significant step forward in the company’s journey towards its RE100 targets and decarbonization goals.With this latest addition, solar capacity at the Roorkee facility has grown sevenfold from 1.0 MWp to 7.0 MWp. Shree Cement’s total solar footprint now stands at an impressive 293.5 MWp, reinforcing its leadership in sustainable manufacturing within India’s cement sector.Ne..

Next Story
Infrastructure Urban

Covestro India, CSIR-NCL Partner to Recycle Polyurethane Waste

Convestro (India) National has signed a Memorandum of Understanding (MOU) with the CSIR- Chemical Laboratory (NCL) launching an innovative Corporate Social Responsibility project aimed at developing sustainable upcycling solutions for polyurethane materials, addressing the critical limitations in current recycling technologies.The collaborative project will explore innovative approaches to transform polyurethane waste into valuable chemical building blocks. This research aims to develop commercially viable technologies that could greatly improve the circularity of polyurethane materials while ..

Next Story
Infrastructure Urban

Aimtron Electronics Raises Rs 1 Bn via Warrants for New Facility

Aimtron Electronics, a fast-growing Electronics System Design and Manufacturing (ESDM) company, hased a fundraise of approximately Rs 1 billion through the issuance of convertible warrants on a preferential basis. The round includes participation from the promoter group including Mukesh Vasani and Nirmal Vasani along with a host of marquee investors.The Board of Directors of Aimtron Electronics has approved the issuance of up to 14,79,000 warrants of the company, at the price of Rs 666 per warrant each convertible into, for one fully paid-up equity share of the company of face value of Rs 10 a..

Advertisement

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Talk to us?